严重胎儿脑室扩大:大型前瞻性队列中的胎儿发病率与死亡率、剖宫产率及产科挑战
这项前瞻性观察研究纳入2011年1月1日至2020年7月31日爱尔兰都柏林国立妇产医院胎儿医学科的95例产前严重脑室扩大(Vp>15 mm)病例,分析染色体异常率、生存率及剖宫产率。总体生存率(排除终止妊娠)为53/74(71.6%),孤立性严重脑室扩大组为20/23(86.9%);总体剖宫产率为47/72(65.3%),显著高于同期医院剖宫产率25.4%(P<0.01)。
要点
- 严重胎儿脑室扩大(Vp>15 mm)队列中,额外结构异常占67/95(70.5%),染色体异常占15/95(15.8%)。
- 排除终止妊娠后总体生存率为53/74(71.6%),孤立性严重脑室扩大组为20/23(86.9%)。
- 总体剖宫产率为47/72(65.3%),显著高于同期医院剖宫产率25.4%(P<0.01)。
核心结论
- 严重胎儿脑室扩大与显著的胎儿发病率和死亡率相关,本队列中剖宫产率较高。
- 在持续妊娠且伴有明显巨头畸形时,分娩计划应个体化,以尽可能改善新生儿结局并尽量减少对母亲的伤害。
研究设计与样本
- 前瞻性观察研究,纳入2011年1月1日至2020年7月31日在爱尔兰都柏林国立妇产医院胎儿医学科就诊的产前严重脑室扩大(Vp>15 mm)患者,共95例妊娠。
- 数据来自医院数据库,统计采用卡方检验,并按Vp<20 mm与Vp>20 mm分为两组比较。
主要发现
- 超声显示额外结构异常67/95(70.5%),孤立性严重脑室扩大28/95(29.5%)。
- 染色体异常15/95(15.8%),孤立性严重脑室扩大组2/28(7.1%) vs 非孤立性组13/67(19.4%)。
- 总体生存率(排除终止妊娠)53/74(71.6%),孤立性严重脑室扩大组20/23(86.9%)。
- 总体剖宫产率47/72(65.3%),显著高于同期医院剖宫产率25.4%(P<0.01)。
- Vp>20 mm组较Vp<20 mm组有更高的额外颅内超声发现率(Vp<20组13/41(31.7%) vs Vp>20组32/54(59.3%),P<0.05)和巨头畸形率(Vp<20组14/41(34.1%) vs Vp>20组35/54(64.8%),P<0.05);两组间总体生存率或剖宫产率无显著差异。
临床怎么用
- 作者认为,在持续妊娠且伴有明显巨头畸形时,分娩计划应个体化,以尽可能改善新生儿结局并尽量减少对母亲的伤害。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Severe fetal ventriculomegaly (VM) is defined as an enlargement of the atria of the lateral cerebral ventricles (Vp) of greater than 15 mm. While it is well established that it confers significant risk of morbidity and mortality to the neonate, there is limited information pertaining to the caesarean delivery rates and the obstetric management of these complex cases. The aim of this study was twofold: firstly, to determine survival rates in fetuses with severe VM, and secondly to determine the caesarean delivery rates in continuing pregnancies. We explore the obstetric challenges associated with these difficult cases. METHODS: This was a prospective observational study of patients with antenatal severe VM, attending the Department of Fetal Medicine, National Maternity Hospital, Dublin, Ireland, from 1st January 2011 to 31st July 2020. Data were obtained from the hospital database and those with severe VM (Vp > 15 mm) were identified. The rates of chromosomal abnormalities, the survival rates and the caesarean delivery (CD) rates for the overall group were then determined. The data were then further sub-divided into two groups: 1. Vp < 20 mm and 2. Vp > 20 mm, and the results compared. Statistical analysis was performed using the Chi-Square test. RESULTS: A total of N = 95 pregnancies with severe VM were included for analysis, of which additional structural abnormalities on ultrasound were apparent in 67/95 (70.5%) and 28/95 (29.5%) had isolated severe VM. Chromosomal abnormalities were diagnosed in 15/95 (15.8%) of cases, with (2/28) 7.1% in the isolated SVM group versus (13/67) 19.4% in the non-isolated SVM group. The overall survival rate (excluding TOP) was 53/74 (71.6%), with 20/23 (86.9%) in the isolated SVM group. The overall CD rate was 47/72 (65.3%), which was significantly higher than the CD for the hospital during the same time period of 25.4% (P < 0.01). The data were subdivided into Vp < 20 and Vp > 20 and those with a Vp > 20 had higher rates of additional intracranial findings on ultrasound (Vp < 20 13/41 (31.7%) versus Vp > 20 32/54 (59.3%) (P < 0.05)) and macrocrania (Vp < 20 14/41 (34.1%) versus Vp > 20 35/54 (64.8%) (P < 0.05)). No significant difference was observed in the overall survival or CD rates between the two groups. CONCLUSION: In conclusion this study reports significant fetal morbidity and mortality with severe VM with high CD rates observed in this cohort. Significant challenges exist in relation to the obstetric management and counseling of parents regarding an often uncertain neonatal prognosis. In continuing pregnancies with significant macrocrania delivery plans should be individualized to improve neonatal outcomes where possible and minimize harm to the mother.
引用
- Start AO, Ryan GA, Cathcart B, et al. Severe fetal ventriculomegaly: Fetal morbidity and mortality, caesarean delivery rates and obstetrical challenges in a large prospective cohort. Prenat Diagn. 2021. PMID: 34870870. doi:10.1002/pd.6072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。